Podium to Practice: Clinical Integration of New Advances in the Treatment of Patients with B-Cell Malignancies Updates from ASCO and EHA

Program Overview
This activity aims to provide healthcare professionals who treat patients with B-cell malignancies with an update of recently presented clinical trial data from the ASCO and EHA Annual Meetings that will impact the care of these patients in 2022 and beyond.

Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with B-cell malignancies.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Assess how recently presented data will impact the future care of patients with aggressive lymphoma subtypes, including Diffuse Large B-cell (DLBCL), Mantle Cell Lymphoma (MCL), and Hodgkin’s Lymphoma (HL)
Evaluate the clinical trial results of current and emerging approaches to the treatment of patients with indolent lymphoma subtypes, including Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL)
Compare recent data of therapies for patients with Chronic Lymphocytic Leukemia (CLL)
Determine how various patient- and disease-related factors impact selection of therapy and sequencing of agents
Develop strategies to integrate novel agents and regimens into practice as they become available in order to improve patient outcomes